Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

Rhea-AI Summary

Daré Bioscience (NASDAQ: DARE) announced the publication of additional data from its Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% in The Journal of Sexual Medicine. The study, focusing on female sexual arousal disorder (FSAD), revealed that 1-month and 24-hour recall patient reported outcome (PRO) instruments yielded similar responses. This finding supports the use of either method for assessing treatment efficacy in future clinical studies, with longer recall intervals being less burdensome for participants and potentially improving data collection compliance.

The company previously announced a positive end-of-Phase 2 meeting with the FDA, supporting the advancement of Sildenafil Cream for FSAD treatment. Daré continues to interact with the FDA on the development program. Efficacy data from the Phase 2b RESPOND study were also published in Obstetrics & Gynecology.

Positive

• Publication of Phase 2b RESPOND study data in The Journal of Sexual Medicine
• Consistency between 1-month and 24-hour recall PRO instruments, offering flexibility in future studies
• Positive end-of-Phase 2 meeting with FDA, supporting advancement of Sildenafil Cream for FSAD treatment
• Publication of efficacy data in Obstetrics & Gynecology journal

Negative

• None.

Insights

Medical Research Analyst

The publication of Phase 2b RESPOND study data for Sildenafil Cream, 3.6% in The Journal of Sexual Medicine is a significant development for Daré Bioscience. The study's findings, showing consistency between 1-month and 24-hour recall patient reported outcomes (PROs), are important for future clinical trials in female sexual arousal disorder (FSAD). This consistency allows for more flexible and patient-friendly data collection methods, potentially improving compliance and data quality.

The strong correlation between different recall periods suggests robust efficacy signals for Sildenafil Cream. This could streamline the path to Phase 3 trials and eventual FDA approval. However, it's important to note that while these results are promising, they are from an exploratory study. The true test will be in the pivotal Phase 3 trials, which will determine if these findings translate into clinically meaningful outcomes for FSAD patients.

Financial Analyst

This news has positive implications for Daré Bioscience's (NASDAQ: DARE) financial outlook. The successful publication and positive results from the Phase 2b study strengthen the company's position in the women's health market. The potential for a less burdensome clinical trial process could lead to cost savings in future studies, positively impacting the company's R&D expenses.

Moreover, the advancement of Sildenafil Cream towards Phase 3 trials could attract partnership opportunities or additional investor interest. However, investors should be cautious as the path to market is still long and further capital may be needed to fund Phase 3 trials. The market for FSAD treatments remains largely untapped, presenting a significant revenue opportunity if Sildenafil Cream gains approval, but also carries the risk of uncertain market adoption.

Market Research Analyst

The publication of these results in a reputable journal like The Journal of Sexual Medicine enhances Daré Bioscience's credibility in the women's health space. The potential for Sildenafil Cream to address FSAD, an often overlooked condition, could open up a new market segment with significant growth potential.

The flexibility in data collection methods could make future trials more appealing to participants, potentially accelerating recruitment and reducing dropout rates. This efficiency could give Daré an edge in bringing a product to market faster than competitors. However, the success of Sildenafil Cream will depend on factors beyond efficacy, including pricing, reimbursement and overcoming potential stigma associated with FSAD. The company's ability to navigate these challenges will be important for market success.

Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that either method could be used to assess treatment efficacy in future clinical studies

Longer recall intervals for PRO assessments are less burdensome to clinical study participants and may improve data collection compliance

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that additional data from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%, an investigational topical cream formulation of sildenafil being developed as an on-demand treatment for female sexual arousal disorder (FSAD), has been published by The Journal of Sexual Medicine.

Publication Details:

Johnson, et al. “Comparisons and correlations of 1-month recall vs 24-hour recall in patient-reported outcomes of an exploratory, phase 2b, randomized, double-blind, placebo-controlled clinical trial of sildenafil cream, 3.6% for the treatment of female sexual arousal disorder.” The Journal of Sexual Medicine, 2024 [Preprint] https://doi.org/10.1093/jsxmed/qdae086

“In this first-of-its-kind study in FSAD patients, we are very pleased to be able to share these data,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “Being able to show consistent results from patient reported outcome measures, regardless of whether she is recalling her experiences over the last month or the last day, provides important optionality as we consider how to clinically measure the impact of Sildenafil Cream on patients with FSAD.”

“This preplanned subset analysis was intended to investigate whether there were differences in outcomes when assessing arousal sensation on 24-hour vs 1-month PRO instruments,” said Dr. Annie Thurman, MD, FACOG, Medical Director at Daré Bioscience. “We were thrilled to see the strong correlation between the 24-hour recall eDiary and the 1-month recall instrument scores since the 1-month recall is significantly less burdensome for patients. With a condition that’s often dismissed and stigmatized, it's important to show that we can collect accurate data to assess efficacy of Sildenafil Cream in a way that’s easily manageable for patients.”

The exploratory Phase 2b RESPOND study was specifically designed to identify the patient population that experienced the most meaningful improvement from Sildenafil Cream and the questions to ask them, or the PRO measures, that best reflect that improvement. The patient population and the endpoints proposed to the U.S. Food and Drug Administration (FDA) for Phase 3 clinical development were those where Daré's exploratory post-hoc analyses of the Phase 2b study data showed that Sildenafil Cream demonstrated statistically significant and meaningful patient improvement. Daré previously announced a positive end-of-Phase 2 meeting with the FDA supporting advancement of Sildenafil Cream for the treatment of FSAD and continues to interact with the FDA on the development program for Sildenafil Cream as a treatment for FSAD.

As previously announced, efficacy data from the Phase 2b RESPOND study were published in Obstetrics & Gynecology, the official publication of the American College of Obstetricians and Gynecologists. The journal article, entitled “Preliminary Efficacy of Topical Sildenafil Cream for the Treatment of Female Sexual Arousal Disorder: A Randomized Controlled Trial,” can be found in the August 2024 issue of Obstetrics & Gynecology 144(2):p 144-152, and is available online at https://journals.lww.com/greenjournal/fulltext/2024/08000/preliminary_efficacy_of_topical_sildenafil_cream.4.aspx.

About FSAD and Sildenafil Cream, 3.6%

FSAD, as described in the DSM-IV, is a condition characterized primarily by a persistent or recurrent inability to attain or maintain sufficient genital arousal (an adequate lubrication-swelling response) during sexual activity, frequently resulting in distress or interpersonal difficulty. FSAD is clinically analogous to erectile dysfunction (ED) in men. As with ED in men, FSAD is associated with insufficient blood flow to the genitalia.

Sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor, is the active ingredient in a tablet for oral administration currently marketed under the brand name Viagra® for the treatment of ED in men. Sildenafil Cream is an investigational, proprietary cream formulation of sildenafil designed for topical administration to the vulvar-vaginal tissue on demand to increase genital blood flow and provide improvements in the female genital arousal response, while avoiding systemic side effects observed with oral formulations of sildenafil.

Market research suggests that 16% of women in the U.S. ages 21 to 60, or approximately 10 million women, are distressed from experiencing symptoms associated with FSAD, including lack of or low sexual arousal, and are actively seeking solutions to improve their condition. In comparison, the prevalence of complete ED in men is estimated to be about 5% of men at age 40, increasing to about 15% at age 70.

About Daré Bioscience

Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility.

The first FDA-approved product to emerge from Daré’s portfolio of women’s health product candidates is XACIATO™ (clindamycin phosphate) vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Organon commenced U.S. marketing of XACIATO in the fourth quarter of 2023. Daré’s portfolio also includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil, the active ingredient in Viagra®, to treat female sexual arousal disorder (FSAD); and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy. To learn more about XACIATO, Daré’s full portfolio of women’s health product candidates, and Daré’s mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

Daré Bioscience leadership has been named on the Medicine Maker’s Power List and Endpoints News’ Women in Biopharma 2022. In 2023, Daré's CEO was honored as one of Fierce Pharma’s Most Influential People in Biopharma for Daré’s contributions to innovation and advocacy in the women’s health space. Daré Bioscience placed #1 in the Small Company category of the San Diego Business Journal’s 2023 Best Places to Work Awards.

Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.

Forward-Looking Statements
Daré cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “objective,” or the negative version of these words and similar expressions. In this press release, forward-looking statements include, but are not limited to, statements relating to Sildenafil Cream’s potential as a safe and effective therapy for FSAD, Daré’s plans for continued clinical development of Sildenafil Cream, including Phase 3 clinical trial design, the potential for Sildenafil Cream to be the first FDA-approved treatment for FSAD, and the potential market opportunity for Sildenafil Cream. As used in this press release, the description of a product candidate as “first-in-category” is a forward-looking statement relating to the potential of the candidate to represent a new category of product if it were to receive marketing approval for the indication for which Daré is developing it. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Daré’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: Daré’s ability to raise additional capital when and as needed to advance its product candidates, execute its business strategy and continue as a going concern; the risk that data from the Phase 2b RESPOND study may not be predictive of positive results of any future clinical study; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with Daré’s interpretation of or conclusions regarding the study data; the risk that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; the risk that development of a product candidate requires more clinical or nonclinical studies than Daré anticipates; Daré’s ability to develop, obtain FDA or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated timelines; failure or delay in starting, conducting and completing clinical trials of a product candidate; Daré’s ability to design and conduct successful clinical trials, to enroll a sufficient number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety and efficacy of its product candidates; Daré’s dependence on third parties to conduct clinical trials and manufacture and supply clinical trial material and commercial product; the loss of, or inability to attract, key personnel; the effects of macroeconomic conditions, geopolitical events, public health emergencies, and major disruptions in government operations on Daré’s operations, financial results and condition, and ability to achieve current plans and objectives; the risk that developments by competitors make Daré’s product or product candidates less competitive or obsolete; difficulties establishing and sustaining relationships with development and/or commercial collaborators; failure of Daré’s product or product candidates, if approved, to gain market acceptance or obtain adequate coverage or reimbursement from third-party payers; Daré’s ability to retain its licensed rights to develop and commercialize a product or product candidate; Daré’s ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its product and product candidates; Daré’s ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Daré’s product candidates which could expose its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations or actions relating to Daré’s product or product candidates or the business activities of Daré, its commercial collaborators or other third parties on which Daré relies; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; cybersecurity incidents or similar events that compromise Daré’s technology systems or those of third parties on which it relies and/or significantly disrupt Daré’s business; and disputes or other developments concerning Daré’s intellectual property rights. Daré’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Daré’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including Daré’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Daré undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Contacts:

Media and Investors on behalf of Daré Bioscience, Inc:

Camilla White / Simona Kormanikova
Dentons Global Advisors
DareBioscience@dentonsglobaladvisors.com / 1.212.466.6450

Source: Daré Bioscience, Inc.

FAQ

What were the key findings of Daré Bioscience's Phase 2b RESPOND study for Sildenafil Cream, 3.6%?

The study found that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar, supporting the use of either method to assess treatment efficacy in future clinical studies for female sexual arousal disorder (FSAD).

How might the findings of the RESPOND study impact future clinical trials for Sildenafil Cream, 3.6% (DARE)?

The findings suggest that longer recall intervals for PRO assessments could be used, which are less burdensome to clinical study participants and may improve data collection compliance in future trials.

What is the current status of Sildenafil Cream, 3.6% (DARE) in the FDA approval process?

Daré Bioscience has had a positive end-of-Phase 2 meeting with the FDA, supporting the advancement of Sildenafil Cream for FSAD treatment. The company continues to interact with the FDA on the development program.

Where have the results of Daré Bioscience's Sildenafil Cream, 3.6% studies been published?

Results have been published in The Journal of Sexual Medicine and Obstetrics & Gynecology, the official publication of the American College of Obstetricians and Gynecologists.